Summary
Johnson & Johnson, through its Janssen Pharmaceutical Companies, announced the significant acquisition of all rights to the investigational compound bermekimab on December 30, 2019. This transaction, valued at $750 million, bolsters Janssen's dermatology pipeline with a compound targeting multiple dermatological indications. The acquisition includes certain employees from XBiotech Inc., indicating a strategic move to integrate talent and expertise. Janssen Research & Development, LLC will spearhead the further development of bermekimab, signaling a commitment to advancing this promising asset.
Key Highlights
- 1Janssen Pharmaceutical Companies acquired all rights to investigational compound bermekimab.
- 2The acquisition cost was $750 million.
- 3Bermekimab is intended for multiple dermatological indications.
- 4Certain employees from XBiotech Inc. were also acquired.
- 5Janssen Research & Development, LLC will be responsible for developing bermekimab.
- 6Potential for additional payments to XBiotech Inc. if bermekimab is pursued for non-dermatological indications.
- 7The acquisition represents a strategic investment in the dermatology sector.